Arca
Skip to content
Tools
Tools

ALDH5A1: Succinate-semialdehyde dehydrogenase, mitochondrial

Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). .

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on ALDH5A1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Valproic acid

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        Valproic acidBoxed warningApprovedAbbVieSmall moleculeInhibitorSuccinate semialdehyde dehydrogenase inhibitor28

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent GliomaValproic acidPhase 2RecruitingInova Health Care ServicesSep 21, 2026
        CS1 Added to Standard of Care Therapy for Pulmonary Arterial HypertensionValproic acidPhase 2Not yet recruitingCereno Scientific ABAug 12, 2026
        Evaluation of Intravenous Sodium Valproate on Interleukin-6 Levels in Patients With TMJ Disc DisplacementValproic acidPhase 2Active, not recruitingTanta UniversityMar 23, 2026
        Valproate for the Treatment of Residual AmblyopiaValproic acidPhase 1 / Phase 2RecruitingBoston Children's HospitalNov 10, 2025
        Valproic AcId for Traumatic BRAin INjury TrialValproic acidPhase 2 / Phase 3Not yet recruitingNorthwestern UniversitySep 10, 2025
        A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or LamotrigineValproic acidPhase 3RecruitingBristol-Myers SquibbAug 26, 2025
        Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.Valproic acidPhase 4Active, not recruitingDr. Stavroula RakitziJul 2, 2025
        Pharmacogenetics-Based Study on Individualized Use of Sodium ValproateValproic acidPhase 4RecruitingThe First Affiliated Hospital of University of South ChinaJul 1, 2025

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Succinic semialdehyde dehydrogenase deficiency0.84
        • Seizure0.59
        • Hereditary disease0.52
        • Generalized non-motor (absence) seizure0.47
        • Complex partial epilepsy0.46
        • Bipolar I disorder0.39
        • Mitochondrial disease0.37

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1911, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P51649, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.